Lung Cancer Study Group

The team of the LCGC Study Center headed by Prof. Jürgen Wolf is located in the Department I of Internal Medicine at the Center for Integrated Oncology at the University Hospital Cologne. We aim to develop more effective treatments for lung cancer.

For this purpose and in close cooperation with the Group of translational cancer genomics, molecular pathology and molecular imaging, we develop our own trial protocols for treating genetically defined lung cancer subgroups and to optimize immunotherapeutic treatment approaches. At the same time we try to transfer findings from pre-clinical research to the clinic quickly and efficiently, which happens within the framework of early translational studies and in collaboration with the pharmaceutical industry.

The LCGC study program strives to provide each patient with a therapeutically relevant genetic aberration in his or her tumor with a specified trial. In order to achieve this objective for the greatest possible number of patients, the doctors of the LCGC-study center also supervise the head office of the Network Genomic Medicine lung cancer. The doctors of the LCGC study center are also working in the specialized outpatient clinics of the Center for Integrated Oncology and at the Department I of Internal Medicine at the University Hospital Cologne in order to ensure optimal care for cancer patients in Cologne.

Last update: 29. February 2016 , 14:32

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.
Share This